Verily Life Sciences Portfolio Exits
6 Portfolio Exits
Verily Life Sciences has 6 portfolio exits. Their latest portfolio exit was Ciitizen on September 07, 2021.
You May Also Like
Cardionomic addresses Acute Decompensated Heart Failure's root cause of reduced contractility. The therapy uses neuromodulation to benignly increase contractility, thus improving cardiac output therefore increasing renal flow and end organ perfusion. Benignly increasing contractility decreases negative hormonal signaling, and improves in-hospital morbidity/mortality.
Neuspera Medical is a medical device startup that leverages exclusively licensed mid-field powering techniques to engineer miniaturized injectable neuromodulation technologies, sometimes referred to as electroceuticals. Neuspera's implantable module is more than 100 times smaller than other neuromodulation devices and may substantially reduce implant procedure complexity, time, patient complication, and post-surgical pain. Neuspera Medical is committed to bringing forward implantable medical device technology that will improve lives of patients battling with chronic illness.
ShiraTronics develops an approach to treat migraine headaches. The company is focused on developing and clinically testing its neuromodulation technology
SetPoint Medical is developing a bioelectronic medicine platform using a small implanted device that activates the body's natural Inflammatory Reflex and produces a systemic anti-inflammatory effect.
LivaNova is a medical device company in the treatment of cardiovascular diseases. The company develops, manufactures, and markets medical technologies for cardiac surgery and for the treatment of cardiac rhythm disorders.
BrainsGate develops a technology for modulation of cerebro-vascular properties through neuro-stimulation of the spheno-palatine ganglion. Affected properties are central to many CNS disorders - blood vessel permeability and blood flow. Currently targeted applications include treatment of ischemic stroke and drug delivery to the CNS through modifying the permeability of the blood brain barrier. The Company has initiated clinical trials, delivering a chemotherapeutic agent to primary brain tumor patients.)
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.